The M&A Pool Set to Accelerate Biotech Innovation
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But...
Listen (13m) | How Long Can the PIPE Success Story Keep Running?
The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in...
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back
U.S. healthcare desperately needs to cut costs and improve outcomes. There is no single solution, but three...
Will the Biotech Rebound Run into Pricing Policy Obstacles?
The biotech industry is poised for an innovation-led rebound, but drug pricing is already in the election...
Few IPOs but plenty of follow-on for biotech in 2023
Biotech continues to bolster the healthcare market, but there are tailwinds for services and HCIT too, as...
ECM: Robust End to Year, Despite Previous Volatility
As RBC Capital Markets looks forward to a robust end to the year, John Hoffman and Jason Levitz, Co-Heads of...
Balancing Act: Biotech Juggles Innovation, Competition, Policy, and Funding
For biotech, innovation is a double-edged sword; competition in the biotech space remains high, with...
Read (4m) | ViewA New Era of Healthcare Innovation
Healthcare and life sciences came out the other side of the pandemic more resilient and bursting with growth...
Read (4m) | ViewRaising capital: A new playbook for a new era in biotech
In a market suppressed by inflation, how can the biotech industry continue to raise essential capital for...
Read (36m) | ViewBiotech Halftime Report: A Winding Road Ahead
While competition and patent cliffs remain overhangs, innovation and regulatory permissiveness remain high...
When to Call it Quits: VCs Making Tough Decisions in a Tough Market
RBC’s Noël Brown, Head of US Biotechnology Investment Banking, recently held an Endpoints roundtable with...
Biotech M&A: Reshaping the Strategic Landscape
Biotech M&A remains a pivotal force in the ever-evolving world of biotech, forging strategic value and...
Key Takeaways from Our Global Healthcare Conference
Disruption, innovation and deal making have been focal points at our annual Global Healthcare conference for...
Read (3m) | ViewBiotech M&A Booms, But Have We Reached A Tipping Point?
Gregory Renza, M.D., Senior Biotechnology Analyst, delves into the driving forces behind the recent surge of...
The Power and Potential of Genetic Medicine
Genetic medicine is poised to unlock more value for patients and investors. RBC’s biotechnology analyst Luca...
The Hidden Revolution Set to Turn US Healthcare on its Head
In this episode of Pathfinders, RBC’s Healthcare Technology Analyst Sean Dodge discusses the value-based...
The Big Picture for Biotech
In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the...
Why Biopharma Investment Requires a Different Mindset
In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital...
The Optimism Behind the Biopharma Market
Dr. Chen Yu, Founder and Managing Partner at TCG X, discusses why he is optimistic about biotech, and what’s...
Biotech Investors: How to Find Value in a Bear Market
How are top investors navigating the longest biotech bear market in almost 20 years?
Serving the Underserved: Global Blood Therapeutics Commitment to Sickle-Cell Innovation
In this rebroadcast interview, Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT)...
Ionis: Raising the Bar for ESG
In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth...
Biotech and Big Pharma: Blueprint for Successful Partnership
As biotech firms and large pharma companies find new synergies to bring new treatments to market together...
Inside Track: Behind the Scenes of a Major Biotech SPAC
RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the...
What’s Material in ESG for Biopharma Firms?
In this episode of Pathfinders, Brian Abrahams, Co-Head of Biotechnology Equity Research at RBC Capital...
Biotech SPACs: A New Route to Going Public
As more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies...
5AM Ventures: Fueling the Next Generation of Innovators
In this episode of Pathfinders, Brian Abrahams, Co-Head of Biotechnology Equity Research at RBC Capital...
Vida Ventures: Powering Breakthroughs in Biopharma
In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Arjun...
Biotech IPOs: Navigating the New Landscape
Even in a boom, biopharma executives will need to stay alert to the risks of undertaking an IPO. Our...
Biotech IPOs: New Steps to Success on the Road to Going Public
In our launch edition of Pathfinders, our investment banking team looks at the best practices to follow on...
Pathfinders in Biopharma Podcast
Our podcast series explores the fast-moving world of biopharma and what the road ahead looks like for companies and investors in the sector.
More Healthcare insights
From biotech breakthroughs to digital transformation, our global healthcare specialists dive deep into the latest trends, innovations, and emerging opportunities.
Stay Informed
Get the latest insights from RBC Capital Markets delivered to your inbox.